Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer
Launched by UNIVERSITY OF OXFORD · May 17, 2018
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
In this feasibility study, we are investigating a novel way to test for remaining or reoccurring oesophageal cancer following chemoradiotherapy. The technique used to test this is called a Cytosponge™. We will be testing the use of the Cytosponge™ to determine completion rate, safety and acceptability of the procedure.
Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the spong...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female, Age \>/=16 years who
- • 1. have undergone pre-operative CRT as treatment for oesophageal cancer and due to undergo oesophagectomy or
- • 2. have undergone definitive CRT as treatment for oesophageal cancer
- • 2. 4-16 weeks post completion of CRT
- • 3. Dysphagia score 0-2 (Mellow Scale)\*
- • 4. Able to swallow tablets
- • 5. Physiologically fit for endoscopy
- • 6. Written (signed and dated) informed consent
- • 7. The patient is willing and able to comply with the protocol for the duration of the study, and scheduled follow-up visits and examinations.
- Exclusion Criteria:
- • 1. Known to have oesophageal varices or stricture requiring dilatation of the oesophagus.
- • 2. Unable to temporarily discontinue anticoagulation therapy/medication prior to their procedure\*
- • 3. Oesophageal stent
- • 4. Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor study candidate or could interfere with protocol compliance or the interpretation of study results.
- • Patients on anti-coagulation therapy are eligible for the study as long as they are considered suitable candidates for endoscopic biopsy (follow local hospital procedures for management of patients on anticoagulation due to undergo endoscopy). If temporary discontinuation of anticoagulation is required, this should be after consultation with the patients clinical care team.
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, , United Kingdom
Leicester, , United Kingdom
Oxford, , United Kingdom
Hull, , United Kingdom
Manchester, , United Kingdom
Bodelwyddan, , United Kingdom
Cardiff, , United Kingdom
Southampton, , United Kingdom
Milton Keynes, , United Kingdom
Cambridge, Please Select An Option Below, United Kingdom
Bristol, , United Kingdom
Wirral, , United Kingdom
Patients applied
Trial Officials
Prof Somnath Mukherjee
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials